Trial Profile
Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Retinal pigment epithelial cell replacement therapy-Cell Cure Neurosciences (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lineage Cell Therapeutics; Roche
- 13 Mar 2024 According to a Lineage Cell Therapeutics media relea, 24 Month results of patients enrolled in a Phase 1/2a clinical study will be presented at 2024 Retinal Cell & Gene Therapy Innovation Summit by David Telander, MD, PhD, Retinal Consultants Medical Group, on behalf of Roche and Genentech.
- 16 Jan 2024 According to a Lineage Cell Therapeutics media release, results from this trial will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting. The virtual meeting will be held on February 3, 2024.
- 24 Oct 2023 According to a Lineage Cell Therapeutics media release, results of imaging analyses from this trial, have been accepted for presentation at Eyecelerator 2023, will be presented as part of the Presenting Company Breakout Session, between 1-2:45pm PDT, by Gary S. Hogge, D.V.M., M.S. Ph.D., Lineage's Senior Vice President, Clinical and Medical Affairs, at American Academy of Ophthalmology (AAO) 2023 Annual Meeting.